Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-133-7 | CAS number: 116-26-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
1. Skin sensitisation: sensitising, Guinea Pig, Open Epicutaneous Test, 1984
2. Skin sensitisation: sensitising, Guinea Pig, Maximisation Test, 1984
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 1984
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Good documented study, although not GLP.
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- By determining carefully all factors favouring contact sensitization and combining them in a single procedure, MAGNUSSON and KLIGMAN (1969, 1970, 1975) developed the so-called Guinea Pig Maximization Test (GMPT).
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- The in vivo study (GPMT) was conducted prior to the implementation of the LLNA method
- Species:
- guinea pig
- Strain:
- Himalayan
- Sex:
- male/female
- Details on test animals and environmental conditions:
- experimental group: 10-20 animals
control or vehicle group: 10-20 animals
primary irritation group: 4 animals
temperature: 22+/- degrees centrigrade
relative humidity: 45 (+/- 10)%
light cycle: 12 hour /day - Route:
- intradermal
- Vehicle:
- physiological saline
- Concentration / amount:
- 1.0.1 ml FCA alone (adjuvant blended with equal amount of water or saline)
2. 0.1 ml test material in saline
3. 0.1 ml test material in FCA - Day(s)/duration:
- DAY 1
- Adequacy of induction:
- not specified
- Route:
- epicutaneous, occlusive
- Vehicle:
- petrolatum
- Concentration / amount:
- Challenge topical occlusive: 10% and 3%
- Day(s)/duration:
- 28 hours
- Adequacy of induction:
- not specified
- No.:
- #1
- Route:
- epicutaneous, occlusive
- Vehicle:
- other: ethanol
- Concentration / amount:
- 10% and 3%
- Day(s)/duration:
- day 21 to day 23 and 24
- Adequacy of challenge:
- highest non-irritant concentration
- No. of animals per dose:
- Experimental group: 10 -20 animals
Control group: 10 - 20 animals
Primary irritation group: 4 animals - Details on study design:
- -On day 1 the animals are injected intradermally with :1. 0.1 ml of 5% solution of the compound; 2. with 0.1 ml of FCA alone and 3. with 0.1 ml of a 5% emulsion of the compound in FCA-each injection is given twice;
-On day 8 the compound in petrolatum up to 25% is applied to a clipped skin area of the neck and kept under patch for 2 days.
-On days 21 an occlusive patch test with the compound in ethanol is applied to the flank for 24 hours. the readings done on 24 and 48 hours after removal of the patch. - Challenge controls:
- Control group: 10 - 20 animals,
-On day 1 the animals are injected intradermally with :1. vehicle; 2. with 0.1 ml of FCA alone and 3. with 0.1 ml of a 5% emulsion of the compound in FCA-each injection is given twice;
-On day 8 the vehicle is applied to a clipped skin area of the neck and kept under patch for 2 days. - Positive control substance(s):
- no
- Key result
- Reading:
- other: Days 23 and 24
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 10%
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- all 20 animals are positive at 10%
- Remarks on result:
- other: Reading: other: Days 23 and 24. . Hours after challenge: 24.0. Group: test group. Dose level: 10%. No with. + reactions: 20.0. Total no. in groups: 20.0.
- Key result
- Reading:
- other: Days 23 and 24
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 3%
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- 20 of 20 animals are positive at 3%
- Remarks on result:
- other: Reading: other: Days 23 and 24. . Hours after challenge: 24.0. Group: test group. Dose level: 3%. No with. + reactions: 20.0. Total no. in groups: 20.0.
- Key result
- Reading:
- other: Days 23 and 24
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 10%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- 0 out of 20 animals are positive in control group
- Remarks on result:
- other: Reading: other: Days 23 and 24. . Hours after challenge: 24.0. Group: negative control. Dose level: 10%. No with. + reactions: 0.0. Total no. in groups: 20.0.
- Key result
- Reading:
- other: Days 23 and 24
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- no positive control
- No. with + reactions:
- 0
- Total no. in group:
- 0
- Clinical observations:
- n/a
- Remarks on result:
- not measured/tested
- Interpretation of results:
- Category 1A (indication of significant skin sensitising potential) based on GHS criteria
- Conclusions:
- Under test conditions safranal induces allergic contact sensitization in all guinea pigs.
- Executive summary:
The study was performed using a Guinea Pig Maximization Test method under GLP.
On the day 1 (Induction - Intradermal application), the animals are injected intradermally with :1. 0.1 ml of 5% solution of the compound; 2. with 0.1 ml of FCA alone and 3. with 0.1 ml of a 5% emulsion of the compound in FCA-each injection is given twice.
On the day 8 (Induction - Topical application): the compound in petrolatum up to 25% is applied to a clipped skin area of the neck and kept under patch for 2 days.
On the day 21 (Challenge): an occlusive patch test with the compound in ethanol is applied to the flank for 24 hours. the readings done on 24 and 48 hours after removal of the patch.
Under test conditions used SAFRANAL induces allergic contact sensitization in all guinea pigs. Additionally, performed open epicutaneous tests with 1% and 0.3% alcoholic solution of the preparation 2 weeks after the occlusive challenge elicit allergic reaction in 20/20 animals.
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- From February 20, 1984 to April 11, 1984
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Good documentation, although not a GLP study.
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- CTFA Safety testing guidelines
- GLP compliance:
- no
- Type of study:
- open epicutaneous test
- Justification for non-LLNA method:
- The in vivo study (OET) was conducted prior to the implementation of the LLNA method
- Species:
- guinea pig
- Strain:
- Himalayan
- Sex:
- male/female
- Details on test animals and environmental conditions:
- Male and female outbred Himalayan white spotted guinea pigs weighing 300 - 450 g, bred at the Institute of Biological Research at Fullinsdorf, Switzerland, are used.
The studies are carried out under standard laboratory conditions. With exception of the treatment periods the animals are caged in wire mesh cages Type 3.
The animal rooms are conditioned:
- Temperature= 22 (+/- 2) degrees centigrade
- Relative humidity= 45 (+/- 10) %
- Light cycle = 12 hours/day
Diet: Pellet standard NAFAG-No. 845 - Ch-9202 Gossau
Water: Tap water ad libitum (water quality according to the requirements of the Schweiz. Lebensmittelbuch). - Route:
- epicutaneous, open
- Vehicle:
- other: ethanol
- Concentration / amount:
- 3, 10, 30, 100 %
- Day(s)/duration:
- Day 1-28
- Adequacy of induction:
- other: application of a 10% alcoholic solution SAFRANAL is well tolerated; repeated applications caused slight skin irritation in the 3rd and 4th week of the treatment
- No.:
- #1
- Route:
- epicutaneous, open
- Vehicle:
- other: ethanol
- Concentration / amount:
- 10%
- Day(s)/duration:
- Day 28
- Adequacy of challenge:
- highest non-irritant concentration
- No.:
- #2
- Route:
- epicutaneous, open
- Vehicle:
- other: ethanol
- Concentration / amount:
- 10%
- Day(s)/duration:
- DAY 42
- Adequacy of challenge:
- highest non-irritant concentration
- No. of animals per dose:
- Experimental group: 4 x 6 guinea pigs
Controls groups: 10 guinea pigs - Details on study design:
- -One day before the induction procedure that threshold toxic of contration is estimated by applying 100, 30, 10 and 3%. The minimal irritating and maximal non-irritating con are determined by an all-or-none criterion.
-Induction, Days 1-21. Day 1 was applied 0.1 ml test materials. The application are repeated daily for 3 weeks or done 5-times weekly for 4 weeks. The application was left uncovered and the reactions can read 24 h after each application.
-Control, 10 untreated or only pretreated with the control.
-Challenge: Days 21-35. Guinea pigs were treated on days 21 and 35 on the contralateral flank with the test material at the minimal irritating and some lower primary nonirritating concentrations. The reactions are read after 24, 48 and/or 72 hours. - Challenge controls:
- Challenge control
-Induction: Control, 10 untreated or only pretreated with the control on Day 1-21.
-Challenge: Days 21-35. Guinea pigs were treated on days 21 and 35 on the contralateral flank with the test material at the minimal irritating and some lower primary nonirritating concentrations. The reactions are read after 24, 48 and/or 72 hours. - Positive control substance(s):
- no
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 100%
- No. with + reactions:
- 1
- Total no. in group:
- 6
- Clinical observations:
- n/a
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 30%
- No. with + reactions:
- 4
- Total no. in group:
- 6
- Clinical observations:
- n/a
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 10%
- No. with + reactions:
- 0
- Total no. in group:
- 6
- Clinical observations:
- n/a
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 3%
- No. with + reactions:
- 0
- Total no. in group:
- 6
- Clinical observations:
- n/a
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 100%
- No. with + reactions:
- 1
- Total no. in group:
- 6
- Clinical observations:
- n/a
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 30%
- No. with + reactions:
- 5
- Total no. in group:
- 6
- Clinical observations:
- n/a
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Reading:
- rechallenge
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 10%
- No. with + reactions:
- 0
- Total no. in group:
- 6
- Clinical observations:
- n/a
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 3%
- No. with + reactions:
- 0
- Total no. in group:
- 6
- Clinical observations:
- n/a
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 3, 10, 30 and 100%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- n/a
- Remarks on result:
- no indication of skin sensitisation
- Group:
- positive control
- Remarks on result:
- not measured/tested
- Interpretation of results:
- Category 1B (indication of skin sensitising potential) based on GHS criteria
- Conclusions:
- A weak to moderate sensitizing potential of safranal under the test conditions used
- Executive summary:
The study was performed using an Open Epicutaneous Test method. The concentrations selected for the main study were based on the results of a preliminary study.
In the main study, induction was via daily topical application of the test item diluted with ethanol to 0% (control), 3%, 10%, 30%, and 100% for 5 days/week between days 1 -28. A treatment group of 6 per concentration and a control group of 10, respectively were on day 28, challenged with the test material at the minimal irritating and some lower primary nonirritating concentrations. Skin reactions were evaluated 24 to 72 hours after challenge treatment.
Single application of a 10% alcoholic solution of SAFRANAL is well tolerated; repeated applications causes light skin irritation in the 3rd and 4th week of the treatment. Higher concentrated alcoholic solutions cause moderate to very strong skin irritation. Then the application sites had to be changed.
Challenge tests with the highest non irritating alcoholic solution of SAFRANAL elicit allergic reactions in guinea pigs pretreated with the undiluted test material and a 30% solution of the preparation.
A weak to moderate sensitizing potential of SAFRANAL could be found under test conditions used.
- Endpoint:
- skin sensitisation: in vitro
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- an in vitro skin sensitisation study does not need to be conducted because adequate data from an in vivo skin sensitisation study are available
- Endpoint:
- skin sensitisation: in chemico
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- From February 06, 2019 to March 15, 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- direct peptide reactivity assay (DPRA)
- Details on the study design:
- Preparation if test solution: Accurately weighed 150.20 mg of Safranal in 10.0 mL volumetric flask, and dissolved in Acetonitrile : Milli Q water (1:1 v/v) and volume was made up to 10 mL with Acetonitrile: Milli Q water ( 1:1 v/v).
Accurately weighed 150.19 mg of Safranal in 10.0 mL volumetric flask, and dissolved in Acetonitrilc : Milli Q water (1:1 v/v) and volume was made up to 10 mL with Acelonitrile : Milli Q water (1:1 v/v).
Preparation of standard solutions: - Cysteine peptide: 0.669 mM stock solutions of cysteine peptide were prepared by diluting 2.51 mg of cysteine peptide with 5.0 mL of Sodium phosphate buffer of pH 7.5.
- Lysine peptide: 0.668 mM stock solutions of lysine peptide was prepared by diluting 2.59 mg of lysine peptide with 5.0 mL of 100 mM ammonium acetate buffer pH 10.2.
Peptide and test item (1:10 Dilution)
- Cysteine Peptide: a volume of 375µL of cysteine stock solution, 400 µL of phosphate bufler pH 7.5, 25 µLof sample stock solution and 200 µL of acetonitrile were added to HPLC vial.
- Lysine Peptide: a volume of 375µL of lysine stock solution, 400 µL of ammonium acetate bufler pH 10.2, 25 µLof sample stock solution and 200 µL of acetonitrile were added to HPLC vial.
Peptide and test item (1:50 Dilution)
- Cysteine Peptide: a volume of 375µL of cysteine stock solution, 300 µL of phosphate bufler pH 7.5, 125 µLof sample stock solution and 200 µL of acetonitrile were added to HPLC vial.
- Lysine Peptide: a volume of 375µL of lysine stock solution, 300 µL of ammonium acetate bufler pH 10.2, 125 µLof sample stock solution and 200 µL of acetonitrile were added to HPLC vial.
HPLC vials were gently vortexed and incubated for 24 hours at 25°C ± 2.5°C in the (dark) prior to HPLC analysis. Preparation was done in triplicates and single HPLC run was performed for each preparation.
Preparation of Control: A volume of 375 µL of cysteine stock solution, 425 µL phosphate buffer pH 7.5 and 200 µL of acetonitrile were added to HPLC vial.
A volume of 375 µL of lysine stock solution, 425 µL ammonium acetate buffer pH 10.2 and 200 µL of acetonitrile were added lo HPLC vial.
HPLC vials will be gently vortexed and incubated for 24 hours at 25°C ± 2.5°C in the dark place prior to HPLC analysis. Preparation was done in triplicates and single HPLC run will be performed for each preparation.
Prepation of Linearity Standards for Cysteine Peptide:
• A volume of 25 µL of cysteine stock solution, 925 µL phosphate buffer pH 7.5 and 50 µL of acetonitrile were added to HPLC vial (0.0167 mM).
• A volume of 50 µL of cysteine stock solution, 900 µL phosphate buffer pH 7.5 and 50 µL of acetonitrile were added to HPLC vial (0.0334 mM).
• A volume of 100 µL of cysteine stock solution, 850 µL phosphate buffer pH 7.5 and 50 µL of acetonitrile were added to HPLC via l (0.0669 mM).
• A volume of 200 µL of cysteine stock solution, 750 µL phosphate buffer pH 7.5 and 50 µL of acetonitrile were added to HPLC vial (0. 1337 mM).
• A volume of 200 µL of cysteine stock solution, 275 µL phosphate buffer pH 7.5 and 25 µL of acetonitrile were added to HPLC vial (0.2674mM).
• A volume of 400 µL of cysleine stock solution, 75 µL phosphate buffer pH 7.5 and 25 µL of acetonitrile were added to HPLC vial (0.5348 mM).
Each standard was injected and a linearity curve was prepared using regression analysis.The correlation coefficient, slope and intercept were calculated.
Prepara tion or Linearity Standard for Lysine Peptide
• A volume of 25 µL of lysine stock solution, 925 µL ammonium acetate buff'er pH 10.2 and 50 µL of acetonitrile were added to HPLC vial (0.0 167 mM).
• A volume of 50 µL of lysine slock solution, 900 µL ammonium acetate buffer pH 10.2 and 50 µL of acetonitrile were added to HPLC vial (0.0334mM).
• A volume of 100 µL of lysine stock solution, 850 µL ammonium acetate buffer pH 10. 2 and 50 µL of acetonitrile were added to HPLC vial (0.0668 mM).
• A volume of 200 µL of lysine stock solution, 750 µL ammonium acetate buffer pH 10.2 and 50µL of acetonitrie were added to HPLC vial (0.1355 mM).
• A volume of 200 µL of lysine stock solution, 275 µL ammonium acetate buffer pH 10.2 and 25 µL of acetonitrile were added to HPLC vial (0.2670 mM).
• A volume of 400 µL of lysine stock solution, 50 µL ammonium acetate buffer pH 10.2 and 25 µL of acetonitrile were added to HPLC vial (0.5341 mM ).
Each standar was injected and a linearity curve was prepared using regression analysis. The correlation coefficient, slope and intercept were calculated.
Analysis: All prepared samples were loaded to HPLC sequence and chromatograms were determined at 220 run. Peptide reactivity with the test item was reported as percent peptide depletion, which was determined as the reductionof the peptide concentration in the samples relative to the average concentration of the controls. - Key result
- Run / experiment:
- other: Cysteine (1:10)
- Parameter:
- other: Mean of Cysteine depletion
- Value:
- 90.63
- Vehicle controls validity:
- not examined
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Run / experiment:
- other: Lysine (1:50)
- Parameter:
- other: Mean of Lysine depletion
- Value:
- 20.81
- Vehicle controls validity:
- not examined
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Remarks on result:
- positive indication of skin sensitisation
- Other effects / acceptance of results:
- The mean value of the percent cysteine and lysine depletion was calculated for the test item. From the mean value of the percent cysteine and lysine depletion, the reactivity class was classified and the skin sensitivity was predicted.
- Interpretation of results:
- Category 1 (skin sensitising) based on GHS criteria
- Conclusions:
- The percent peptide depletion was 90.63% for cysteine peptide solution and 20.81% for lysine peptide solution. The mean value of the percent cysteine ad lysine depletion was 55.72%. Therefore, the reactivity class of test item was classified to " High Reactivity Sensitizer" and skin sensitivity was predicted as " Positive" in these testing conditions.
- Executive summary:
The objective of the study was to screen the test item Safranal for skin sensitizing potential by direct peptide reactivity assay (DPRA).
The test item dissolved in acetonitrile was mixed with cysteine peptide solution (1:10) and lysine peptide solution (1:50) respectively, was incubated at25±2.5°C for 24 hours. After 24hours of incubation the reaction solutions were analysed by high performance liquid chromatography and peak area for each peptide was determined. Percent cysteine and percent lysine peptide depletion, and the average value of the percent peptide depletions were calculated.
Consequently, the percent peptide depletion was 90.63% for cysteine peptide solution (1:10) and 20.81% for lysine peptide solution (1:50). The mean value of the percent cysteine and lysine depletion was 55.72%.Therefore,the reactivity class of test item was classified to" High Reactivity sensitizer"and skin sensitivity was predicted as "Positive".
Referenceopen allclose all
Skin irritation results:
a) After single application
Solvent Concentration lowest irritation Concentration highest non irritating ethanol 30%10%
b) After repeated application of during 28 sucessive days - except week end
Skin irritation after days :
Concentration% 7 14 21 28 100 strong * strong* strong* strong 30 moderate strong* strong* very strong 10 none none slight slight 3 none none none none
* application sites were changed
Since application of a 10% alcoholic solution SAFRANAL is well tolerated; repeated applications caused slight skin irritation in the 3rd and 4th week of the treatment. Higher concentrated alcoholic solutions cause moderate to very strong skin irritation. Then the application sites had to be changed.
Allergic sensitization:
Sensitization rate Day 28 Sensitization rate Day 42 After daily application during 4 weeks of Chall Conc% Animals positive/total Chall Conc% Animals positive/total Concentration 100% 10 1/6 101/6 Concentration 30% 10 4/6 10 5/6 Concentration 10% 10 0/6 10 0/6 Concentration 3% 10 0/610 0/6
Evaluation Method:
Mean of Cysteine and Lysine depletion | Reactivity Class | Prediction |
0% < Mean % Depletion < 6.38% | Minimal Reactivity Non- Sensitiser | Negative |
6.38% < Mean % Depletion < 22.62% | Low Reactivity Sensitiser | Positive |
22.62% < Mean % Depletion < 42.47% | Moderate Reactivity Sensitiser | |
42.47%< Mean % Deplet ion < 100 % | High Reactivity Sensitiser |
Results:
Particulars | Sample Code | Sample Peak Area (mAU) | Mean Sample Peak Area (mAU) | Percent Peptide Depletion | Mean Percent Peptide Depletion |
Cysteine (1:10) | Control R1 | 1144.19 | 12 16.98 | - | - |
Control R2 | 1260.77 | ||||
Control R3 | 1245.99 | ||||
Sample Rl | 119.62 | - | 90.17 | 90.63 | |
Sample R2 | 108.2 2 | 91.11 | |||
Sample R3 | I14.21 | 90.62 | |||
Lysine (1:50) | Control R1 | 680.48 | 704.435 | - | - |
Control R2 | 724.98 | ||||
Control R3 | 707.85 | ||||
Sample RI | 544.9 | - | 22.65 | 20.81 | |
Sample R2 | 553.78 | 21.39 | |||
Sample R3 | 574.76 | 18.41 | |||
Average Percent Depiction |
55.72 | ||||
Prediction |
High Reactivitv |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
Two old in vivo studies but well documented studies indicating sensitisation.
Weight of Evidence : in vivo, Open Epicutaneous Test (OET), 1984 : The concentrations selected for the main study were based on the results of a preliminary study. In the main study, induction was via daily topical application of the test item diluted with ethanol to 0% (control), 3%, 10%, 30%, and 100% for 5 days/week between days 1 -28. A treatment group of 6 per concentration and a control group of 10, respectively were on day 28, challenged with the test material at the minimal irritating and some lower primary nonirritating concentrations. Skin reactions were evaluated 24 to 72 hours after challenge treatment. Single application of a 10% alcoholic solution of SAFRANAL is well tolerated; repeated applications causes light skin irritation in the 3rd and 4th week of the treatment. Higher concentrated alcoholic solutions cause moderate to very strong skin irritation. Then the application sites had to be changed. Challenge tests with the highest non irritating alcoholic solution of SAFRANAL elicit allergic reactions in guinea pigs pretreated with the undiluted test material and a 30% solution of the preparation.
A weak to moderate sensitizing potential of SAFRANAL could be found under test conditions used.
Weight of Evidence: The study was performed using a Guinea Pig Maximization Test method under GLP
On the day 1 (Induction - Intradermal application), the animals are injected intradermally with :1. 0.1 ml of 5% solution of the compound; 2. with 0.1 ml of FCA alone and 3. with 0.1 ml of a 5% emulsion of the compound in FCA-each injection is given twice.
On the day 8 (Induction - Topical application): the compound in petrolatum up to 25% is applied to a clipped skin area of the neck and kept under patch for 2 days.
On the day 21 (Challenge): an occlusive patch test with the compound in ethanol is applied to the flank for 24 hours. the readings done on 24 and 48 hours after removal of the patch.
Under test conditions used SAFRANAL induces allergic contact sensitization in all guinea pigs. Additionally, performed open epicutaneous tests with 1% and 0.3% alcoholic solution of the preparation 2 weeks after the occlusive challenge elicit allergic reaction in 20/20 animals.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Self-classification:
Based on the available information, the substance meets classification criteria under Regulation (EC) No. 1272/2008 (CLP) and to the GHS for skin sensitisation category 1A.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.